Head-to-head · WeighScore
Velvet Rx vs Zealthy
The verdict
Velvet Rx takes it — 58.1/100 to 46.7/100.
Velvet Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Velvet Rx (velvetrx.com) is a cash-pay telehealth platform offering compounded semaglutide, compounded tirzepatide, and an oral GLP-1 across three publicly-listed SKUs ranging from $139 to $199 'today'…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Velvet Rx | Zealthy |
|---|---|---|
| WeighScore | 58.1/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #381 | #496 |
| Semaglutide | $299/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $359/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #381 · C
Strengths
- Public pricing across 3 SKUs (semaglutide $299, tirzepatide $359, oral GLP-1 $349) — uncommon in compounded telehealth
- First-month promo pricing shown upfront ($139 sema / $199 tirz / $189 oral)
- Single monthly price includes consult, prescription, 4 weeks of medication, and free 1–2 day shipping
- FSA/HSA eligible
- Three options under one roof: injectable sema, injectable tirz, and an oral GLP-1
Where it loses points
- Oral GLP-1 SKU doesn't name the specific drug — a real gap given Rybelsus, Foundayo, and compounded oral semaglutide differ clinically
- No LegitScript or NABP .pharmacy seal displayed
- No legal entity name disclosed
- No physical address disclosed
- Compounding pharmacy partner not named
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.